{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+IR+tablets&page=2", "query": { "intervention": "Metformin IR tablets", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+IR+tablets&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T12:39:52.748Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02221180", "title": "Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bioequivalence" ], "interventions": [ { "name": "Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2014-08", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-11-25", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02221180" }, { "nct_id": "NCT01864174", "title": "Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Metformin XR", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Placebo matching with Metformin XR", "type": "DRUG" }, { "name": "Placebo matching with Metformin IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1736, "start_date": "2013-06-20", "completion_date": "2016-06-01", "has_results": true, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01864174" }, { "nct_id": "NCT00897390", "title": "Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin IR (glucophage)", "type": "DRUG" }, { "name": "Saxagliptin + Metformin IR (FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "19 Years to 45 Years" }, "enrollment_count": 24, "start_date": "2009-06", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2015-05-21", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897390" }, { "nct_id": "NCT02206607", "title": "Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "PF-04937319 IR MST", "type": "DRUG" }, { "name": "PF-04937319 MR 1", "type": "DRUG" }, { "name": "PF-04937319 MR 2", "type": "DRUG" }, { "name": "PF-04937319 MR 3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2014-09", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-03-04", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 2, "location_summary": "High Point, North Carolina • San Antonio, Texas", "locations": [ { "city": "High Point", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206607" }, { "nct_id": "NCT01454622", "title": "A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)", "type": "DRUG" }, { "name": "B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2011-09", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-05-06", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01454622" }, { "nct_id": "NCT01434186", "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo matching with Saxagliptin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" }, { "name": "Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 32, "start_date": "2012-05", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 7, "location_summary": "Los Angeles, California • Tallahassee, Florida • Dearborn, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Dearborn", "state": "Michigan" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01434186" }, { "nct_id": "NCT01508195", "title": "A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin tablets", "type": "DRUG" }, { "name": "Metformin IR tablets", "type": "DRUG" }, { "name": "Canagliflozin/metformin IR FDC tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2012-01", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508195" }, { "nct_id": "NCT02220218", "title": "Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2014-08", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02220218" }, { "nct_id": "NCT04854512", "title": "Investigational Study of Delayed Release Metformin", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Metformin DR", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Metformin DR Placebo", "type": "DRUG" }, { "name": "Metformin IR placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anji Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 675, "start_date": "2021-05-18", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 33, "location_summary": "Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854512" }, { "nct_id": "NCT04885530", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 10956, "start_date": "2021-06-08", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-09-28T12:39:52.748Z", "location_count": 110, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04885530" } ] }